These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24051927)

  • 1. Antitumor effect of everolimus in a patient with type 3 gastric neuroendocrine tumor.
    Bariani GM; Carvalheira JB; Riechelmann RP
    Onkologie; 2013; 36(9):502-4. PubMed ID: 24051927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
    Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
    Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compassionate use of everolimus in a patient with a neuroendocrine tumor: a case report and discussion of the literature.
    Pusceddu S; Milione M; Procopio G
    Oncol Res; 2011; 19(8-9):403-6. PubMed ID: 22329200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report.
    Nakayama Y; Ikeda M; Kojima M; Goto K; Hara M; Okuyama H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Okusaka T
    Chemotherapy; 2013; 59(1):74-8. PubMed ID: 23867634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.
    Flaum N; Valle JW; Mansoor W; McNamara MG
    Future Oncol; 2016 Nov; 12(22):2561-2578. PubMed ID: 27412069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
    Thompson LA; Kim M; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of everolimus in pancreatic neuroendocrine tumors.
    Goldstein R; Meyer T
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroendocrine tumors: treatment updates.
    Khagi S; Saif MW
    JOP; 2013 Jul; 14(4):367-71. PubMed ID: 23846929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel agents in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R; Libutti SK; Saif MW
    JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
    Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
    Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L; Schwarz RE
    Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted agents in treatment of neuroendocrine tumors of pancreas.
    Karampelas IN; Syrigos KN; Saif MW
    JOP; 2014 Jul; 15(4):351-3. PubMed ID: 25076341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequencing and combining systemic therapies for pancreatic neuroendocrine tumors.
    Kulke MH
    J Clin Oncol; 2015 May; 33(14):1534-8. PubMed ID: 25870092
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral agents for treatment of patients with advanced pancreatic neuroendocrine tumors: could pharmaeconomic, cost-effectiveness data play a significant role?
    Barna ME; Uomo I; Pastorello M
    JOP; 2013 Jan; 14(1):102-4. PubMed ID: 23306347
    [No Abstract]   [Full Text] [Related]  

  • 17. New target therapies for patients with neuroendocrine tumors of the pancreas.
    Baltogiannis G; Katsios C; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2011 Oct; 5(5):563-6. PubMed ID: 21910571
    [No Abstract]   [Full Text] [Related]  

  • 18. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
    Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
    Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus for the treatment of pancreatic neuroendocrine tumors.
    Feldmann G; Bisht S; Schütte U; Haarmann J; Brossart P
    Expert Opin Pharmacother; 2012 Oct; 13(14):2073-84. PubMed ID: 22873789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus dramatically improves glycemic control in unresectable metastatic insulinoma: a case report.
    Asayama M; Yamada-Murano T; Hara H; Ooki A; Kurosumi M; Yamaguchi K
    Jpn J Clin Oncol; 2014 Feb; 44(2):186-90. PubMed ID: 24367043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.